Skip to main content

Fibrolamellar Carcinoma clinical trials at UCSD
1 research study open to eligible people

  • Neratinib HER Mutation Basket Study (SUMMIT)

    open to eligible people ages 18 years and up

    This is an open-label, non-randomized, multicenter, multinational, Phase 2 study exploring the efficacy and safety of neratinib as monotherapy or in combination with other therapies in patients with ERBB mutation-positive or EGFR gene-amplified solid tumors.

    La Jolla, California and other locations

Last updated: